All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2025-02-26.
From the record
Outset Medical, Inc.'s filings since 2017 show 2 warning events: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2025-02-26) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+79.3% a year over 8 filed years; profitable in 0 of 8.
From the record
Outset Medical, Inc.'s 8 filed years say what it did: revenue went from $2 million in fiscal 2018 to $119 million in fiscal 2025, up 79.3% a year; it rose in 6 of 7 years; the deepest fall was 13% from fiscal 2023 to fiscal 2024; net income was positive in 0 of 8 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 2.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Outset Medical, Inc.'s shareholder treatment is put at 2.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 28% of 27 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -64%: lost 64¢ per shareholder dollar. Leverage 52%: owes 52¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Outset Medical, Inc. lost about 64 cents for every dollar of shareholders' money, and gross profitability: its products earned about 18 cents per dollar of everything the company owns. Leverage: it owed about 52 cents per dollar of assets, and net share issuance: its share count grew 339.2% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 45% of 24 in its family; net margin -68.3%.
From the record
Outset Medical, Inc.'s standing among 24 graded names in its industry family: revenue of $119 million in fiscal 2025 ranks in the top 31% by size; a net margin of -68.3% ranks in the bottom 40%; revenue growth of 1.2% a year over the last 3 filed years ranks in the bottom 26% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 47% of 19 in its family for leadership; chief executive since 2020.
From the record
Outset Medical, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Trigg, Leslie (Chair and CEO, as filed), filing under that title since 2020-09-14, 6.2 years (top 19% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 3.3 years (bottom 38%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 11 people in charge now (bottom 22%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 33% of 23 in its family for room to expand.
From the record
Outset Medical, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $35 million against debt of $96 million leaves -23.2% of its assets as net cash, bottom 13% of its family; cash from operations less capital spending is -39.4% of revenue (bottom 41%); a gross margin of 39.1% (bottom 15%); research spending of 17.8% of revenue (top 39%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 10% of 25 in its family for growth drivers.
From the record
Outset Medical, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 1.2% a year over the last three filed years against 79.3% over all 8, slowing (bottom 7% of its family); the newest year grew 5.1% (bottom 15%); research spending grew -24.2% a year (bottom 6%); capital spending grew -54.2% a year (bottom 10%) (its annual reports). Outset Medical, Inc. reported 3 product lines in fiscal 2025: Consumables Product at $54 million (45%), Service and Other Revenue at $35 million (29%), Consoles Product at $31 million (26%); 3 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 28% of 20 in its family for expectations against reality.
From the record
Outset Medical, Inc.'s newest year against its own record: revenue of $119 million in fiscal 2025 came in 5.9% above the $113 million its prior three years' pace pointed to (top 36% of its family); net income of $82 million against a prior three-year average of $155 million (top 20%); a net margin of -68.3% against losses larger than its revenue before (top 27%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made